Nyxoah SA (FRA:5YI)
Germany · Delayed Price · Currency is EUR | Market Cap | 151.31M -41.5% |
| Revenue (ttm) | 15.33M +251.2% |
| Net Income | -83.65M |
| EPS | -2.11 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,000 |
| Open | 1.344 |
| Previous Close | 1.294 |
| Day's Range | 1.296 - 1.626 |
| 52-Week Range | 1.218 - 7.650 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Nyxoah
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. [Read more]
Financial Performance
In 2025, Nyxoah's revenue was 10.02 million, an increase of 121.63% compared to the previous year's 4.52 million. Losses were -90.09 million, 52.1% more than in 2024.
Financial StatementsNews
Nyxoah to Host Investor Day in New York on July 8, 2026
Nyxoah to Host Investor Day in New York on July 8, 2026 Leadership team and Board will discuss the U.S. commercial execution, growth strategy and key priorities Mont-Saint-Guibert, Belgium – June 23, ...
Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 9, 2026
REGULATED INFORMATION June 19, 2026, 10:30pm CET / 4:30pm ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to ...
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 17, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Law of May 2, 20...
Nyxoah Receives $15 Million from the European Investment Bank
Nyxoah Receives $15 Million from the European Investment Bank Non-dilutive debt funding complements the Company's June equity raise, bringing total capital raised to $110 million Mont-Saint-Guibert, B...
Nyxoah price target lowered to $3 from $5 at Stifel
Stifel lowered the firm’s price target on Nyxoah (NYXH) to $3 from $5 and keeps a Hold rating on the shares after updating the firm’s model for the company’s recent…
Information on the total number of voting rights and shares
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 10, 2026 , 11:00 pm CET / 5:00 pm ET – In accordance with article 15 of the Law of ...
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch Mont-Saint-Guibert, Belgium – June 10, 2026, 10:30 pm CET / 04:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (...
Nyxoah Announces Closing of Underwritten Public Offering
REGULATED INFORMATION Nyxoah Announces Closing of Underwritten Public Offering Mont-Saint-Guibert, Belgium – June 10, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Ny...
Nyxoah 55.23M share Spot Secondary priced at $1.72
The offering is expected to close on or around June 9, subject to the satisfaction of customary closing conditions. Nyxoah (NYXH) intends to use the net proceeds from the offering…
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Pricing of $95 Million Underwritten Public Offering Mont-Saint-Guibert, Belgium – June 5, 2026, 5:25 pm CET / 11:25 am ET – Nyxoah SA (Euronex...
Nyxoah S.A. trading halted, news pending
09:51 EDT Nyxoah (NYXH) S.A. trading halted, news pending
Nyxoah announces offering of ordinary shares, no amount given
Nyxoah (NYXH) SA announced the commencement of a proposed underwritten public offering in the United States, which may include shares sold in a private offering to certain qualified or institutional…
Nyxoah announces plan to transition to U.S.-based CEO
Nyxoah (NYXH) announced the commencement of a leadership transition process. Following seven years leading Nyxoah, Olivier Taelman, together with the board of directors, has decided that this is the r...
Nyxoah Announces Proposed Offering of Ordinary Shares
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Proposed Offering of Ordinary Shares Mont-Saint-Guibert, Belgium – June 4, 2026, 10:02 pm CET / 4:02 pm ET – Nyxoah SA (Euronext Brussels/Nasd...
Nyxoah Enters New Chapter of Long Term Value Creation
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Enters New Chapter of Long Term Value Creation Commencement of process to transition to a U.S.-based CEO Transition to support further acceleration of c...
Nyxoah Slides: Corporate presentation
Nyxoah has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Information on the total number of voting rights and shares
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), May 20, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2...
Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum
Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum
Nyxoah Transcript: Bank of America Global Healthcare Conference 2026
A differentiated neuromodulation solution for obstructive sleep apnea is gaining rapid U.S. adoption, with strong clinical outcomes and robust financial growth. Expansion in Europe shows swift market share gains, and future plans focus on innovation and AI-driven care.
Nyxoah price target lowered to $7 from $9 at Piper Sandler
Piper Sandler lowered the firm’s price target on Nyxoah (NYXH) to $7 from $9 and keeps an Overweight rating on the shares following quarterly results. Genio launch appears to be…
Nyxoah Q1 Earnings Call Highlights
Nyxoah NASDAQ: NYXH reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the compan...
Nyxoah reports Q1 EPS (EUR 0.37) vs. (EUR 0.60) last year
Reports Q1 revenue EUR 6.37M vs. EUR 1.06M last year. “Our first quarter revenue results reflect strong execution of our U.S. launch. The 25% sequential quarterly revenue growth was driven…
Nyxoah Earnings Call Transcript: Q1 2026
Q1 2026 saw 13% sequential worldwide revenue growth, led by a 25% U.S. increase and strong account activation. Gross margin was impacted by production issues but is expected to recover, with full-year revenue guidance set at EUR 36-40 million and stable reimbursement outlook.
Nyxoah Earnings release: Q1 2026
Nyxoah released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.